Factors Associated with Reaching Mid-Parental Height in Patients Diagnosed with Inflammatory Bowel Disease in Childhood and Adolescent Period
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The recent update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease initiative has added normal growth in children as an intermediate target in Crohn’s disease and ulcerative colitis. We aimed to investigate factors associated with reaching mid-parental height (MPH) in patients diagnosed with inflammatory bowel disease in childhood and the adolescent period. Methods: This multicenter retrospective observational study included pediatric patients with inflammatory bowel disease that had reached adult height. Factors associated with reaching MPH were investigated by logistic regression analyses. Results: A total of 166 patients were included in this study (128 Crohn’s disease and 38 ulcerative colitis). Among them, 54.2% (90/166) had reached their MPH. Multivariable logistic regression analysis revealed that height Z-score at diagnosis and MPH Z-score were independently associated with reaching MPH (odds ratio [OR], 8.45; 95% confidence interval [CI], 4.44 to 17.90; p<0.001 and OR, 0.11; 95% CI, 0.04 to 0.24; p<0.001, respectively). According to the receiver operating characteristic curve analysis, the optimal cutoff level of "height Z-score at diagnosis minus MPH Z-score" that was associated with reaching MPH was –0.01 with an area under the curve of 0.889 (95% CI [0.835 to 0.944], sensitivity 88.9%, specificity 84.2%, positive predictive value 87.0%, negative predictive value 86.5%, p<0.001). Conclusions: Height Z-score at diagnosis and MPH Z-score were the only factors associated with reaching MPH. Efforts should be made to restore growth in pediatric patients who present with a negative “height Z-score at diagnosis minus MPH Z-score.”
Abstract
Background/Aims: The recent update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease initiative has added normal growth in children as an intermediate target in Crohn’s disease and ulcerative colitis. We aimed to investigate factors associated with reaching mid-parental height (MPH) in patients diagnosed with inflammatory bowel disease in childhood and the adolescent period. Methods: This multicenter retrospective observational study included pediatric patients with inflammatory bowel disease that had reached adult height. Factors associated with reaching MPH were investigated by logistic regression analyses. Results: A total of 166 patients were included in this study (128 Crohn’s disease and 38 ulcerative colitis). Among them, 54.2% (90/166) had reached their MPH. Multivariable logistic regression analysis revealed that height Z-score at diagnosis and MPH Z-score were independently associated with reaching MPH (odds ratio [OR], 8.45; 95% confidence interval [CI], 4.44 to 17.90; p<0.001 and OR, 0.11; 95% CI, 0.04 to 0.24; p<0.001, respectively). According to the receiver operating characteristic curve analysis, the optimal cutoff level of "height Z-score at diagnosis minus MPH Z-score" that was associated with reaching MPH was –0.01 with an area under the curve of 0.889 (95% CI [0.835 to 0.944], sensitivity 88.9%, specificity 84.2%, positive predictive value 87.0%, negative predictive value 86.5%, p<0.001). Conclusions: Height Z-score at diagnosis and MPH Z-score were the only factors associated with reaching MPH. Efforts should be made to restore growth in pediatric patients who present with a negative “height Z-score at diagnosis minus MPH Z-score.”
참고문헌 (34)
- Heuschkel R, "Guidelines for the management of growth failure in childhood inflammatory bowel disease", Inflamm Bowel Dis, 14, pp.839~849 (2008)
- Hildebrand H, "Longitudinal growth in children and adolescents with inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 18, pp.165~173 (1994)
- Turner D, "STRIDE-II : an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE)initiative of the International Organization for the Study of IBD(IOIBD). Determining therapeutic goals for treat-to-target strategies in IBD", Gastroenterology, 160, pp.1570~1583 (2021)
- Shamir R, "Growth retardation in pediatric Crohn's disease : pathogenesis and interventions", Inflamm Bowel Dis, 13, pp.620~628 (2007)
- Ley D, "Growth pattern in paediatric Crohn disease is related to inflammatory status", J Pediatr Gastroenterol Nutr, 63, pp.637~643 (2016)
- Alemzadeh N, "Adult height in patients with early onset of Crohn's disease", Gut, 51, pp.26~29 (2002)
- Sawczenko A, "Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease", Pediatrics, 118, pp.124~129 (2006)
- Levine A, "ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents", J Pediatr Gastroenterol Nutr, 58, pp.795~806 (2014)
- Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease : the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)
- Hyams JS, "Development and validation of a pediatric Crohn's disease activity index", J Pediatr Gastroenterol Nutr, 12, pp.439~447 (1991)
- Turner D, "Management of paediatric ulcerative colitis, part 1 : ambulatory carean evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition", J Pediatr Gastroenterol Nutr, 67, pp.257~291 (2018)
- Tanner JM, "Standards for children's height at ages 2-9 years allowing for heights of parents", Arch Dis Child, 45, pp.755~762 (1970)
- Kim JH, "The 2017 Korean National Growth Charts for children and adolescents : development, improvement, and prospects", Korean J Pediatr, 61, pp.135~149 (2018)
- Lee JJ, "Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score", Inflamm Bowel Dis, 16, pp.1669~1677 (2010)
- Koh SJ, "Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease", Intest Res, 21, pp.43~60 (2023)
- Na SY, "Korean clinical practice guidelines on biologics and small molecules for moderateto-severe ulcerative colitis", Intest Res, 21, pp.61~87 (2023)
- Singh A, "Use of thiopurines in inflammatory bowel disease : an update", Intest Res, 20, pp.11~30 (2022)
- Kang B, "Early biologic treatment in pediatric Crohn's disease : catching the therapeutic window of opportunity in early disease by treat-to-target", Pediatr Gastroenterol Hepatol Nutr, 21, pp.1~11 (2018)
- Kang B, "Mucosal healing in paediatric patients with moderate-to-severe luminal Crohn's disease under combined immunosuppression : escalation versus early treatment", J Crohns Colitis, 10, pp.1279~1286 (2016)
- Burnham JM, "Whole body BMC in pediatric Crohn disease : independent effects of altered growth, maturation, and body composition", J Bone Miner Res, 19, pp.1961~1968 (2004)
- Malik S, "Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction", J Pediatr Gastroenterol Nutr, 52, pp.31~37 (2011)
- Newby EA, "Interventions for growth failure in childhood Crohn's disease", Cochrane Database Syst Rev, 2005, pp.CD003873~ (2005)
- Sanderson IR, "Remission induced by an elemental diet in small bowel Crohn's disease", Arch Dis Child, 62, pp.123~127 (1987)
- Connors J, "Exclusive enteral nutrition therapy in paediatric Crohn's disease results in long-term avoidance of corticosteroids : results of a propensity-score matched cohort analysis", J Crohns Colitis, 11, pp.1063~1070 (2017)
- Cohen-Dolev N, "Differences in outcomes over time with exclusive enteral nutrition compared with steroids in children with mild to moderate Crohn's disease : results from the GROWTH CD study", J Crohns Colitis, 12, pp.306~312 (2018)
- Walters TD, "Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease", Inflamm Bowel Dis, 13, pp.424~430 (2007)
- Church PC, "Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease", Inflamm Bowel Dis, 20, pp.1177~1186 (2014)
- Borrelli O, "Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease", Dig Liver Dis, 36, pp.342~347 (2004)
- Choi J, "Early infliximab yields superior long-term effects on linear growth in pediatric Crohn's disease patients", Gut Liver, 12, pp.255~262 (2018)
- Walters TD, "Growth improvement with adalimumab treatment in children with moderately to severely active Crohn's disease", Inflamm Bowel Dis, 23, pp.967~975 (2017)
- Varille V, "Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn's disease", J Pediatr Gastroenterol Nutr, 23, pp.13~19 (1996)
- Carmichael CM, "A cross-sectional examination of height, weight, and body mass index in adult twins", J Gerontol A Biol Sci Med Sci, 50, pp.B237~B244 (1995)
- Dubois L, "Genetic and environmental contributions to weight, height, and BMI from birth to 19 years of age : an international study of over 12, 000twin pairs", PLoS One, 7, pp.e30153~ (2012)
- Phillips K, "Quantitative genetic analysis of longitudinal trends in height : preliminary results from the Louisville Twin Study", Acta Genet Med Gemellol(Roma), 39, pp.143~163 (1990)